MARKET

HEPA

HEPA

Hepion Pharmaceuticals Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.590
+0.030
+1.92%
After Hours: 1.610 +0.02 +1.26% 19:59 05/14 EDT
OPEN
1.559
PREV CLOSE
1.560
HIGH
1.620
LOW
1.550
VOLUME
881.85K
TURNOVER
--
52 WEEK HIGH
4.830
52 WEEK LOW
1.450
MARKET CAP
121.20M
P/E (TTM)
-0.6261
1D
5D
1M
3M
1Y
5Y
The Daily Biotech Pulse: CorMedix Slumps On Delay In Resubmission of DefenCath NDA, Apellis Awaits FDA Decision, Vera Therapeutics Debuts
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 13)
Benzinga · 2d ago
Hepion Pharmaceuticals Completes Final Patient Recruitment in Phase 2a 'AMBITION' Clinical Trial of CRV431 for the Treatment of Advanced NASH
EDISON, N.J., May 06, 2021 (GLOBE NEWSWIRE) -- Hepion Pharmaceuticals, Inc. (NASDAQ:HEPA), a clinical stage biopharmaceutical company focused on the development of therapeutic drugs for the treatment of liver disease arising from non-alcoholic steatohepati...
GlobeNewswire · 05/06 12:45
BRIEF-Hepion Pharmaceuticals Completes Final Patient Recruitment In Phase 2A Trial Of CRV431
reuters.com · 05/06 11:46
4 Penny Stocks To Buy Now With Price Targets Up To 302%
Apr 02, 2021 (Penny Stocks via COMTEX) -- Analysts Say Buy These Penny Stocks; Do You Agree? Many have taken an interest in penny stocks over the last year....
Penny Stocks · 04/02 20:09
BRIEF-Hepion Pharmaceuticals Files For Mixed Shelf Of Up To $350 Million
reuters.com · 04/02 19:28
10-K: HEPION PHARMACEUTICALS, INC.
(EDGAR Online via COMTEX) -- ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS You should read the following...
Edgar Online - (EDG = 10Q, 10K) · 03/31 20:59
ENDRA Life Sciences Reports 2020 Fourth Quarter and Full Year Financial Results, Provides Business Update
March 25, 2021 (ACCESSWIRE via COMTEX) -- Conference call begins at 4:30 p.m. Eastern time today ANN ARBOR, MI / ACCESSWIRE / March 25, 2021 /ENDRA Life...
ACCESSWIRE · 03/25 20:06
Brookline Capital Markets Sticks to Their Buy Rating for Hepion Pharmaceuticals (HEPA)
SmarterAnalyst · 03/23 18:45
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of HEPA. Analyze the recent business situations of Hepion Pharmaceuticals Inc through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 3 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average HEPA stock price target is 6.33 with a high estimate of 8.00 and a low estimate of 5.00.
EPS
Institutional Holdings
Institutions: 49
Institutional Holdings: 7.19M
% Owned: 9.43%
Shares Outstanding: 76.23M
TypeInstitutionsShares
Increased
14
2.86M
New
8
182.72K
Decreased
2
179.52K
Sold Out
6
1.15M
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.85%
Pharmaceuticals & Medical Research
+1.12%
Key Executives
Chairman/Director
Gary Jacob
Chief Executive Officer/Chief Scientific Officer/Director
Robert Foster
Chief Financial Officer
John Cavan
Other
Todd Hobbs
Independent Director
Thomas Adams
Independent Director
Timothy Block
Independent Director
John Brancaccio
Independent Director
Arnold Lippa
Independent Director
Peter Wijngaard
No Data
About HEPA
Hepion Pharmaceuticals Inc., formerly ContraVir Pharmaceuticals, Inc., is a clinical stage biopharmaceutical company. The Company is focused on the development of targeted therapies for liver disease arising from non-alcoholic steatohepatitis (NASH) and chronic hepatitis virus infection. Its lead oral drug candidate, CRV431, reduces liver fibrosis and hepatocellular carcinoma tumor burden in experimental models of NASH. CRV431 is also being developed for viral hepatitis-induced liver disease. CRV431 targets multiple biochemical pathways involved in the progression of liver disease.

Webull offers kinds of Hepion Pharmaceuticals Inc stock information, including NASDAQ:HEPA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, HEPA stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading HEPA stock methods without spending real money on the virtual paper trading platform.